Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
BUSINESS ACCOUNT
Sign up for a business account to:
-
Access reports individually or via Subscription
-
Receive monthly invoices with payment via CSA or hard dollars
Get access to other exclusive features
-
Analyst access
-
Free Trial Subscriptions
-
Team account with shared subscriptions
-
Advanced analytics to track research consumption and performance
Ingird Gafanhão
- Ingird Gafanhão
In a prime position to execute or to be acquired
The first data presented for all adult r/r ALL patients treated in the FELIX phase 2 trial was positively straightforward with i) consistent response rates that compare well to competing therapies, ii) outstanding safety which is superior to competing therapies, and iii) industry standard ability t
Alex Cogut ... (+3)
- Alex Cogut
- Ingird Gafanhão
- Oscar Haffen Lamm
KOL dinner with Dr Bruce Levine: improved access to cell therapies is ...
We hosted a KOL dinner with Dr Bruce Levine in the context of the International Society for Cell & Gene Therapy (ISCT) conference in Paris. The discussion focused on a few clear points i) to understand a cell product, you need to understand the process, and ii) broader access to cell therapies
Paul de Froment
- Paul de Froment
Paul de Froment ... (+2)
- Paul de Froment
- Thomas Mordelle
Groundbreaking collaboration with Indorama Ventures
Carbios and Indorama Ventures have reaffirmed their partnership through a non-binding Memorandum of Understanding (MOU) to establish a Joint Venture for the construction of the world's first PET biorecycling plant, namely the Reference Unit, in Longlaville (France). While Carbios' investment detail
Gregory Ramirez
- Gregory Ramirez
Thibault Morel
- Thibault Morel
Cedric Rossi
- Cedric Rossi
HUGO BOSS: Successful execution and healthy geo mix lead to raised FY2...
HUGO BOSS - NEUTRAL | EUR68 vs. EUR64 Successful execution and healthy geo mix lead to raised FY22 guidance Strong sales and EBIT beat in Q2 driven by execution… … and low exposure to China’s lockdowns FY22 sales and EBIT guidance revised upwards and we increase our FY22-23 estimates by 7%
Clement Genelot
- Clement Genelot